GoodRx (NASDAQ:GDRX) Reaches New 12-Month Low – Time to Sell?

GoodRx Holdings, Inc. (NASDAQ:GDRX) reached a new 52-week low during trading on Tuesday . The stock traded as low as $2.40 and last traded at $2.3750, with a volume of 543404 shares traded. The stock had previously closed at $2.52.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on GDRX shares. JPMorgan Chase & Co. reduced their price objective on GoodRx from $6.00 to $5.00 and set an “overweight” rating for the company in a research report on Tuesday, November 11th. Wall Street Zen downgraded GoodRx from a “buy” rating to a “hold” rating in a research note on Sunday. Citigroup decreased their price target on GoodRx from $5.00 to $4.50 and set a “buy” rating for the company in a research note on Friday, January 9th. Jefferies Financial Group lowered GoodRx to a “hold” rating in a report on Thursday, January 22nd. Finally, UBS Group reaffirmed a “reduce” rating on shares of GoodRx in a report on Monday, January 5th. Five analysts have rated the stock with a Buy rating, six have assigned a Hold rating and three have given a Sell rating to the company’s stock. According to data from MarketBeat, GoodRx has a consensus rating of “Hold” and an average price target of $4.73.

GoodRx Price Performance

The company has a 50 day moving average of $2.74 and a two-hundred day moving average of $3.64. The firm has a market cap of $799.36 million, a P/E ratio of 26.28, a PEG ratio of 0.97 and a beta of 1.45. The company has a quick ratio of 3.11, a current ratio of 3.11 and a debt-to-equity ratio of 0.81.

GoodRx (NASDAQ:GDRX) last issued its quarterly earnings results on Tuesday, November 4th. The company reported $0.08 earnings per share for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.01). GoodRx had a net margin of 3.97% and a return on equity of 9.73%. The business had revenue of $196.03 million during the quarter, compared to analyst estimates of $195.17 million. During the same period in the previous year, the company posted $0.08 earnings per share. GoodRx’s revenue was up .4% compared to the same quarter last year. Sell-side analysts expect that GoodRx Holdings, Inc. will post 0.13 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the business. Lazard Asset Management LLC lifted its position in shares of GoodRx by 43.6% during the 2nd quarter. Lazard Asset Management LLC now owns 17,142 shares of the company’s stock valued at $85,000 after acquiring an additional 5,201 shares during the last quarter. Brevan Howard Capital Management LP raised its position in shares of GoodRx by 7.7% during the third quarter. Brevan Howard Capital Management LP now owns 95,483 shares of the company’s stock worth $404,000 after purchasing an additional 6,842 shares during the period. Tower Research Capital LLC TRC lifted its holdings in shares of GoodRx by 202.3% during the second quarter. Tower Research Capital LLC TRC now owns 11,327 shares of the company’s stock valued at $56,000 after purchasing an additional 7,580 shares during the last quarter. Quarry LP purchased a new stake in shares of GoodRx during the third quarter valued at $33,000. Finally, Cetera Investment Advisers acquired a new position in shares of GoodRx in the 2nd quarter valued at $50,000. Institutional investors and hedge funds own 63.77% of the company’s stock.

About GoodRx

GoodRx Holdings, Inc (NASDAQ: GDRX) operates a digital healthcare platform designed to help consumers compare prescription drug prices at retail pharmacies across the United States. Through its website and mobile applications, GoodRx aggregates pricing and discount information from a wide network of pharmacies, enabling users to access coupons and savings programs on both generic and brand-name medications. The platform also features price transparency tools that inform patients about cost variations and available discounts to alleviate the financial burden of prescription medications.

In addition to its core drug pricing service, GoodRx offers telehealth services under the GoodRx Care brand, providing virtual consultations for a range of non-emergency conditions and prescription needs.